Hydronephrosis in advanced ovarian carcinoma.
In a consecutive series of 232 patients with ovarian carcinoma, (FIGO IIB-IV), receiving combination chemotherapy, 52 patients (22%) presented with (early, 69%) or developed (late, 31%) hydronephrosis diagnosed by intravenous pyelography or abdominal ultrasound scan. Unilateral hydronephrosis was seen in 77%, bilateral in 23%. Patients with hydronephrosis were characterized by stage IIIB-IV (67%), and primary residual tumor size greater than 2 cm (81%). Nine patients (17%) developed concomittantly impaired renal function diagnosed by a rise in se-creatinine and/or a decrease in 51Cr-EDTA clearance. No difference in survival was seen in patients with early or late hydronephrosis, nor with uni- or bilateral hydronephrosis, but patients with hydronephrosis at the start of chemotherapy lived significantly shorter than those without hydronephrosis, P less than .05. In conclusion, hydronephrosis is a common complication to advanced ovarian carcinoma, and the presence of this complication at the start of chemotherapy has a negative impact on survival.
Lund
B
B
Department of Oncology B, Finsen Institute, Copenhagen, Denmark.
Hansen
H H
HH
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003404:Creatinine / Q000097:blood; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D006869:Hydronephrosis / Q000175:diagnosis / Q000209:etiology*; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D012189:Retrospective Studies; D014463:Ultrasonography; D014567:Urography
D003404:Creatinine